Miransertib: Clinical Trials

3 trials of Miransertib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 1 terminated. 3 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Active not recruiting 2, Terminated 1
Phase 11Terminated 1

Follow Miransertib: new trials by email Literature Review of Miransertib trials Research Report on Miransertib

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
MK-7075 (Miransertib) in Proteus Syndrome
MK-7075 (miransertib) - Proteus Syndrome
Phase 2Active not recruitingNational Human Genome Research Institute (NHGRI)382022-05-202026-07-17
A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)
Miransertib - PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)
Phase 2Active not recruitingMerck Sharp & Dohme LLC602021-11-022025-02-07
Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)
Miransertib - PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome
Phase 1 / Phase 2TerminatedArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)502017-05-162023-04-13

Conditions studied

Congenital Abnormalities (2)  ·  Hereditary Sensory and Autonomic Neuropathies (2)  ·  Proteus Infections (1)  ·  Proteus Syndrome (1)

Sponsors

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (1)  ·  Merck Sharp & Dohme LLC (1)  ·  National Human Genome Research Institute (NHGRI) (1)

Countries

United States (3)  ·  Australia (2)  ·  Italy (2)  ·  Brazil (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Leslie G Biesecker, M.D. (1)

Results publications

PMID 33639990, PMID 40713644, PMID 42224880

NIH funding

2016 (1)